SynthesisReviews in endocrine & metabolic disorders2026
Site-specific fracture risk in chronic hypoparathyroidism: systematic review and meta-analysis.
Synthesis in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hypoparathyroidism (HypoPT) is characterized by sustained parathyroid hormone (PTH) deficiency, leading to reduced bone turnover, increased bone mineral density (BMD), and altered skeletal microarchitecture. Despite preserved or elevated BMD, fracture risk in HypoPT remains controversial. We conducted a systematic review and meta-analysis to assess site-specific fracture risk and the influence of disease duration in patients with chronic HypoPT. Fifteen observational studies, including 13,563 HypoPT subjects and 137,245 controls, were analyzed. HypoPT subjects had a significantly higher risk of vertebral fractures (VFs) than controls (OR 1.88, 95% CI 1.23-2.88), with the excess risk confined to individuals with non-surgical disease (OR 3.05, 95% CI 1.68-5.54). No significant difference between HypoPT and controls were observed in non-vertebral (OR 1.01 (95% CI 0.83, 1.22) or hip fractures (OR 0.81, 95% CI 0.63-1.04). Meta-regression analyses demonstrated that longer median disease duration was associated with higher fracture prevalence at non-vertebral and hip sites. These findings support a site-specific pattern of skeletal fragility, characterized by increased vertebral vulnerability, particularly in non-surgical HypoPT, alongside relative protection at cortical-predominant sites. Fracture risk in HypoPT appears to evolve over time and to become evident during long-term follow-up. Longitudinal, site-directed fracture assessment should be considered in clinical practice.
Indexed as
Identifiers
42113458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.